2,061
Views
2
CrossRef citations to date
0
Altmetric
CHEERS Statement 2022

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1-7 | Received 16 Nov 2021, Accepted 02 Dec 2021, Published online: 10 Jan 2022

References

  • Pitt C, Goodman C, Hanson K. Economic evaluation in global perspective: a bibliometric analysis of the recent literature. Health Econ 2016;25(Suppl 1):9–28.
  • Neumann PJ, Thorat T, Shi J, Saret CJ, Cohen JT. The changing face of the cost-utility literature, 1990-2012. Value Health 2015;18:271–7.
  • Panzer AD, Emerson JG, D’Cruz B, et al. Growth and capacity for cost-effectiveness analysis in Africa. Health Econ 2020;29:945–54.
  • Husereau D, Drummond M, Petrou S, et al; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231–50.
  • Caulley L, Catalá-López F, Whelan J, et al. Reporting guidelines of health research studies are frequently used inappropriately. J Clin Epidemiol 2020;122:87–94.
  • Emerson J, Panzer A, Cohen JT, et al. Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS One 2019;14:e0205633.
  • Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann Intern Med 1995;123:61–70.
  • Gold MR. Cost-effectiveness in health and medicine. Oxford University Press, 1996.
  • Drummond MF, Jefferson TO; The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275–83.
  • Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339–41.
  • Nuijten MJ, Pronk MH, Brorens MJA, et al. Reporting format for economic evaluation. Part II: Focus on modelling studies. Pharmacoeconomics 1998;14:259–68.
  • Vintzileos AM, Beazoglou T. Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. Am J Obstet Gynecol 2004;191:1070–6.
  • Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165–71.
  • Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health 2015;18:161–72.
  • Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications. BMC Health Serv Res 2008;8:270.
  • Davis JC, Robertson MC, Comans T, Scuffham PA. Guidelines for conducting and reporting economic evaluation of fall prevention strategies. Osteoporos Int 2011;22:2449–59.
  • Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011;342:d1548.
  • Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ 2011;342:d1766.
  • Sanghera S, Frew E, Roberts T. Adapting the CHEERS Statement for reporting cost-benefit analysis. Pharmacoeconomics 2015;33:533–4.
  • Walker DG, Wilson RF, Sharma R, et al. Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools. Agency for Healthcare Research and Quality, 2012. https://www.ncbi.nlm.nih.gov/books/NBK114545/
  • Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054–60.
  • Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–103.
  • CADTH.ca. Guidelines for the economic evaluation of health technologies: Canada. 2015. https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada.
  • EUnetHTA European Network for Health Technology Assessment. Practical considerations when critically assessing economic evaluations. Guidance document. 2021. https://eunethta.eu/wp-content/uploads/2020/03/EUnetHTA-JA3WP6B2-5-Guidance-Critical-Assessment-EE_v1-0.pdf
  • Thorn J, Ridyard C, Hughes D, et al. Health economics analysis plans: Where are we now? Value Health 2016;19:A397. .
  • Dunlop WCN, Mason N, Kenworthy J, Akehurst RL. Benefits, challenges and potential strategies of open source health economic models. Pharmacoeconomics 2017;35:125–8.
  • Jansen JP, Incerti D, Linthicum MT. Developing open-source models for the US health system: practical experiences and challenges to date with the open-source value project. Pharmacoeconomics 2019;37:1313–20.
  • Smith R, Schneider P. Making health economic models Shiny: A tutorial. Wellcome Open Res 2020;5:69.
  • ISPOR. Open source models. https://www.ispor.org/member-groups/special-interest-groups/open-source-models.
  • Cohen JT, Neumann PJ, Wong JB. A call for open-source cost-effectiveness analysis. Ann Intern Med 2017;167:432–3.
  • WHO. WHO guide for standardization of economic evaluations of immunization programmes. https://www.who.int/publications/i/item/WHO-IVB-19.10.
  • Mauskopf J, Standaert B, Connolly MP, et al. Economic analysis of vaccination programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value Health 2018;21:1133–49.
  • Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative reference case for economic evaluation: an aid to thought. Value Health 2016;19:921–8.
  • Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. Health Econ Policy Law 2009;4:231–45.
  • Cookson R, Griffin S, Norheim OF, Culyer AJ, Chalkidou K. Distributional cost-effectiveness analysis comes of age. Value Health 2021;24:118–20.
  • Lorgelly PK. Patient and public involvement in health economics and outcomes research. Patient 2021;14:379–80.
  • Ryan M, Moran PS, Harrington P, et al. Contribution of stakeholder engagement to the impact of a health technology assessment: an Irish case study. Int J Technol Assess Health Care 2017;33:424–9.
  • Hawton A, Boddy K, Kandiyali R, Tatnell L, Gibson A, Goodwin E. Involving patients in health economics research: “The PACTS Principles”. Patient 2021;14:429–34.
  • Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Explanation and Elaboration: A report of the ISPOR CHEERS II Good Practices Task Force. Value Health 2022;
  • Malone DC, Ramsey SD, Patrick DL, et al. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. Value Health 2020;23:409–15.
  • Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med 2010;7:e1000217.
  • Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ 2017;358:j3453.
  • Drummond M. Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press, 2015.
  • Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5–14.
  • Crown W, Buyukkaramikli N, Thokala P, et al. Constrained optimization methods in health services research-an introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value Health 2017;20:310–9.
  • Bond K, Stiffell R, Ollendorf DA. Principles for deliberative processes in health technology assessment. Int J Technol Assess Health Care 2020;1–8.
  • ISPOR. Consolidated Health Economic Evaluation Reporting Standards (CHEERS). https://www.ispor.org/CHEERS.
  • Altman DG, Simera I. A history of the evolution of guidelines for reporting medical research: the long road to the EQUATOR Network. J R Soc Med 2016;109:67–77.
  • Catalá-López F, Caulley L, Ridao M, et al. Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. BMJ Open 2020;10:e034463.
  • Sperber AD. Translation and validation of study instruments for cross-cultural research. Gastroenterology 2004;126(Suppl 1):S124–S8.